MARTINSRIED, Germany, June 21, 2007 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment) announced today that an undisclosed partner has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody in the therapeutic area of oncology. This achievement marks the third fully human antibody developed with MorphoSys’s core technology within its partnerships to enter human clinical trials and triggers a clinical milestone payment to MorphoSys.
